The U.S. Food and Drug Administration (FDA) has granted fast track status to RV001, RhoVac‘s investigational therapy for prostate cancer, the company announced. Fast track designation helps speed the approval of potential medicines that address unmet medical needs in serious or life-threatening conditions. It grants RhoVac greater access to FDA input throughout the regulatory process and makes RV001 eligible for accelerated approval and priority review, if it meets certain criteria. With the fast track designation,…
You must be logged in to read/download the full post.
The post FDA Puts RV001 on Fast Track for Treating Prostate Cancer appeared first on BioNewsFeeds.